These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9351492)

  • 1. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R; Schlegel S; Hiemke C; Nickel O; Bockisch A; Rao ML; Hahn K
    Psychiatry Res; 1997 Sep; 75(2):103-14. PubMed ID: 9351492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
    Schlegel S; Schlösser R; Hiemke C; Nickel O; Bockisch A; Hahn K
    Psychopharmacology (Berl); 1996 Apr; 124(3):285-7. PubMed ID: 8740053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
    Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
    Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in D2 dopamine receptor binding in drug-naive patients with schizophrenia: an [123I]iodobenzamide single photon emission computed tomography study.
    Schröder J; Bubeck B; Silvestri S; Demisch S; Sauer H
    Psychiatry Res; 1997 Sep; 75(2):115-23. PubMed ID: 9351493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.
    Dresel S; Mager T; Rossmüller B; Meisenzahl E; Hahn K; Möller HJ; Tatsch K
    Eur J Nucl Med; 1999 Aug; 26(8):862-8. PubMed ID: 10436199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.
    Knable MB; Heinz A; Raedler T; Weinberger DR
    Psychiatry Res; 1997 Sep; 75(2):91-101. PubMed ID: 9351491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
    Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
    Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
    Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].
    Künstler U; Hohdorf K; Regenthal R; Seese A; Gertz HJ
    Nervenarzt; 2000 May; 71(5):373-9. PubMed ID: 10846712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects.
    Scherer J; Tatsch K; Schwarz J; Oertel WH; Konjarczyk M; Albus M
    Acta Psychiatr Scand; 1994 Oct; 90(4):266-8. PubMed ID: 7831996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment.
    Schröder J; Silvestri S; Bubeck B; Karr M; Demisch S; Scherrer S; Geider FJ; Sauer H
    Biol Psychiatry; 1998 May; 43(9):660-5. PubMed ID: 9582999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
    Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.